Key Takeaways
  • Mod GRF 1-29, modified GRF (1-29), tetrasubstituted GRF(1-29) and CJC-1295 without DAC are commercial names for the same 29-residue peptide. The compound described in the published literature as CJC-1295 is the 30-residue version carrying the Drug Affinity Complex (DAC), so the phrase CJC-1295 without DAC is a contradiction in terms.
  • The two forms share an identical receptor-binding sequence. The DAC version adds one lysine bearing a maleimide group that reacts covalently with cysteine-34 of circulating albumin, which converts a short-lived peptide into one carried by a long-lived plasma protein.
  • In the published phase 1 work, the serum half-life of CJC-1295 with DAC was 5.8 to 8.1 days, a single injection raised mean plasma GH 2 to 10-fold for 6 days or more and mean IGF-I 1.5 to 3-fold for 9 to 11 days (Teichman et al., 2006).
  • One week after a single injection of CJC-1295 with DAC, trough GH rose 7.5-fold and mean GH rose 46% while pulse frequency and amplitude were statistically unchanged (Ionescu and Frohman, 2006). The DAC form lifts the baseline rather than abolishing pulsatility.
  • Every published human study of this molecule used the DAC form. A literature search returns no human trial of the tetrasubstituted peptide without DAC, so claims about Mod GRF 1-29 in humans are extrapolation from a shared mechanism, not measured data.
  • Neither form is approved as a medicine in the United States or the European Union, and growth hormone releasing factors including GHRH analogues are prohibited at all times under section S2 of the WADA Prohibited List.
  • The two forms differ by roughly 279 Da. A mass spectrum on a batch-specific certificate of analysis is the only practical way to confirm which one is actually in a vial.
Mod GRF 1-29 vs CJC-1295 DAC at a glance
Mod GRF 1-29
A 29-residue GHRH analogue with four stabilising substitutions and no albumin-binding linker, cleared from plasma within a short window.
Short-acting GHRH signalling studies
vs
CJC-1295
The same peptide backbone extended by a lysine bearing a maleimide linker that binds albumin covalently, giving a reported serum half-life of 5.8 to 8.1 days.
Sustained GHRH exposure research
Get lab-tested CJC-1295
Mod GRF 1-29 is the relevant form if the research question concerns brief GHRH receptor stimulation with no accumulation between administrations.
CJC-1295 with DAC is the relevant form if the research question concerns continuous GHRH exposure, and published human pharmacokinetic data matter.

Why do two different names describe almost the same peptide?

The short answer belongs at the top of this page: Mod GRF 1-29 is CJC-1295 without the DAC. The names modified GRF (1-29), Mod GRF 1-29, tetrasubstituted GRF(1-29) and CJC-1295 no DAC all refer to one 29-amino-acid peptide. The compound that scientists called CJC-1295 in the peer-reviewed literature is a different, slightly larger molecule: the same backbone plus a thirtieth residue carrying a linker called the Drug Affinity Complex.

That is why the expression CJC-1295 without DAC is self-contradictory. The DAC is not an optional accessory bolted onto CJC-1295; it is the feature that defined CJC-1295 as a distinct development candidate in the first place. Strip the linker away and what remains is a stabilised GHRH fragment that was never given the CJC-1295 code name in any published study.

The confusion has a commercial origin rather than a scientific one. CJC-1295 is the name attached to published human pharmacology, so it carries recognition value. The no-DAC peptide has no trial identity of its own in the clinical literature, so vendors began selling it under the better-known label with a qualifier. Two decades later, the same vial can be described as Mod GRF 1-29 on one site and CJC-1295 (no DAC) on another, with no chemical difference between them.

The practical cost of this naming drift is that evidence gets transplanted from one molecule to the other. When a product page states that CJC-1295 has a half-life measured in days, that figure comes from the albumin-binding version and does not describe the no-DAC peptide at all. If you are mapping the broader pharmacology of this family first, the CJC-1295 monograph covers the parent compound in more depth, and this page deals only with what separates the two forms.

Regulators and anti-doping bodies, for what it is worth, do distinguish the members of this family by code name. Lists of growth hormone releasing factors name several analogues separately, including CJC-1293 and CJC-1295, which is a useful reminder that the marketplace vocabulary and the scientific vocabulary are not the same thing.

What exactly differs in the structure of the two forms?

Native human GHRH is a 44-residue hormone, but its growth-hormone-releasing activity resides in the first 29 residues. That fragment, GRF(1-29) amide, is the basis of sermorelin and of both forms discussed here. The starting point for Mod GRF 1-29 and CJC-1295 is therefore the same biologically active N-terminal fragment.

Four amino acid substitutions are applied to that fragment: D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27. The position 2 change is the pharmacologically decisive one. Plasma degradation of GHRH proceeds mainly through dipeptidyl peptidase IV, which cleaves the peptide at the bond between residues 2 and 3, a mechanism characterised by Frohman and colleagues using the DPP IV inhibitor diprotin A. Replacing the natural L-alanine with its D-isomer removes that cleavage site. The three remaining substitutions are chemical stability measures aimed at residues prone to deamidation, rearrangement and oxidation.

Mod GRF 1-29 stops there. It is 29 residues, with a reported molecular formula of C₁₅₂H₂₅₂N₄₄O₄₂ and a molecular weight of about 3367.9 g/mol. There is nothing in the molecule designed to keep it in circulation beyond the resistance conferred by those four substitutions.

CJC-1295 adds one element: a thirtieth residue, a lysine, whose side chain carries a maleimidopropionyl group. This raises the reported molecular weight to about 3647.18 g/mol with a formula of C₁₆₅H₂₆₉N₄₇O₄₆. The difference between the two molecules is therefore roughly 279 Da, a single conjugation handle, and nothing else.

Because the receptor-binding region is untouched, the two forms are not expected to differ in what they do at the GHRH receptor. They differ in how long they are present to do it. Every downstream contrast in this comparison, the half-life, the shape of the GH curve, the accumulation of IGF-I, flows from that one linker rather than from any difference in intrinsic activity.

How does the DAC bind to albumin, and why does that change everything?

A maleimide group is a thiol-reactive Michael acceptor. In plasma, the dominant free thiol is the single unpaired cysteine of serum albumin, cysteine-34. When the DAC-bearing peptide enters the circulation, the maleimide forms a covalent thioether bond with that cysteine. The conjugation step happens inside the body rather than in the manufacturing plant, which is the elegant part of the design: the vial contains a small peptide, and the long-acting drug assembles itself on the patient's own carrier protein.

The preclinical work that established this concept was published in Endocrinology in 2005 by Jetté and colleagues, who showed that hGRF(1-29) albumin bioconjugates still activate the GRF receptor on the rat anterior pituitary and identified CJC-1295 as a long-lasting GRF analogue. The important finding was not simply that the peptide survived longer, but that it remained pharmacologically active while tethered to a 66 kDa protein.

Serum albumin is an attractive carrier because it is abundant, it is too large for glomerular filtration, and it recycles through the neonatal Fc receptor pathway, giving it a plasma residence measured in weeks rather than minutes. A peptide welded to albumin inherits a substantial fraction of that longevity. This is the same general strategy used in several approved long-acting products, so the pharmacological logic is well established even though CJC-1295 itself never reached the market.

Mod GRF 1-29 has no equivalent anchor. It circulates as a free peptide, it is small enough to be filtered by the kidney, and its persistence depends only on resistance to enzymatic cleavage. The consequence is a brief pulse of GHRH receptor stimulation rather than a continuous one.

One further implication deserves mention. Because the DAC form becomes part of an albumin adduct, it also creates a modified self-protein. Immunogenicity of peptide conjugates is one of the concerns the FDA has raised about this substance class in its compounding review material, and it is a theoretical risk that has no counterpart with an unconjugated peptide.

How long does each form stay in circulation?

Native GHRH sets the baseline. Unmodified GHRH and its 1-29 fragment are cleared from plasma within minutes, with degradation driven mainly by dipeptidyl peptidase IV and to a lesser extent by trypsin-like enzymes. Human pharmacokinetic studies of GHRH(1-29) amide after intravenous or intranasal administration confirm an exposure window of minutes, not hours.

For Mod GRF 1-29, the honest answer is that no published human pharmacokinetic study exists. The four substitutions clearly remove the main cleavage site, so a longer plasma survival than native GHRH is a reasonable mechanistic inference. The widely repeated figure of roughly thirty minutes, however, does not trace back to any peer-reviewed human measurement that can be verified. Treating it as an established number is a mistake, and any page that presents it as a trial result is citing the internet rather than the literature.

For CJC-1295 with DAC, the numbers are published. In the phase 1 programme reported by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006, in healthy subjects aged 21 to 61 years, the serum half-life of CJC-1295 was 5.8 to 8.1 days. A single subcutaneous injection produced dose-dependent increases in mean plasma GH of 2 to 10-fold for 6 days or more, and in mean plasma IGF-I of 1.5 to 3-fold for 9 to 11 days. After multiple administrations, mean IGF-I levels remained above baseline for up to 28 days.

That last detail is the one most often overlooked. A compound with a multi-day half-life accumulates when given repeatedly, and its downstream marker, IGF-I, lags behind it. The pharmacokinetic gap between the two forms is therefore not a matter of degree. One produces a transient signal that resolves the same day, the other produces a standing elevation that persists for weeks after the final administration.

This page does not discuss how either compound might be administered. The pharmacokinetic contrast is presented here only to explain why evidence about one form cannot be read across to the other.

Does each form produce pulsatile or sustained growth hormone release?

Growth hormone is not secreted continuously. The pituitary releases it in discrete bursts, with the largest pulses occurring during slow-wave sleep and with low interpulse troughs in between. The pattern itself carries biological information: continuous and pulsatile exposure to the same total amount of GH do not produce identical effects in target tissues. This is the physiological reason the pulsatile question is asked about every GHRH analogue.

A short-acting GHRH analogue such as Mod GRF 1-29 stimulates the receptor for a brief window, so the predicted effect is a discrete GH rise that decays, superimposed on whatever the pituitary was doing anyway. That prediction is mechanistically sound and it is why the no-DAC form is often described as the more physiological of the two. It is also, strictly speaking, untested: no published overnight sampling study has measured the GH profile of the tetrasubstituted peptide without DAC in humans.

The DAC form has been measured. Ionescu and Frohman studied healthy men with frequent overnight blood sampling and reported in 2006 that one week after a single injection of CJC-1295, basal or trough GH levels were markedly increased, by 7.5-fold, while mean GH rose 46% and IGF-I rose 45%. Crucially, the frequency and magnitude of GH secretory pulses were not significantly altered. Their conclusion was that pulsatile secretion persists during continuous stimulation.

That nuance matters and is frequently reported backwards. Continuous GHRH exposure did not flatten the GH rhythm into a plateau. It raised the floor between pulses while the pulses themselves continued, which means the dominant change was a higher integrated GH exposure driven mostly by trough levels rather than by bigger peaks.

The pulsatility debate is also what drives most of the interest in combining a GHRH analogue with a growth hormone secretagogue of the ghrelin-mimetic class, a comparison covered separately in Ipamorelin vs CJC-1295 and in the discussion of the CJC-1295 and ipamorelin combination. Those pages address the mechanistic rationale; nothing here should be read as a suggestion to use any of these compounds.

What human evidence actually exists for each form?

This is where the comparison becomes lopsided. All published human data on this molecule concern the DAC version. There are three relevant human publications. Teichman and colleagues reported the pharmacokinetics, pharmacodynamics and safety of CJC-1295 in healthy adults in 2006. Ionescu and Frohman reported the overnight GH secretory profile in healthy men in the same year. Sackmann-Sala and colleagues later published a serum proteomic analysis in Growth Hormone and IGF Research, examining protein profile changes in normal adult subjects after activation of the GH and IGF-1 axis by CJC-1295.

The supporting preclinical work is also DAC-based. In the rat pituitary studies by Jetté and colleagues, albumin bioconjugates of hGRF(1-29) activated the GRF receptor. In GHRH knockout mice, Alba and colleagues reported in the American Journal of Physiology Endocrinology and Metabolism that once-daily administration of CJC-1295 normalised growth, with treated knockout animals showing normal body weight and length. These are genuine demonstrations of biological activity, in animals.

Development then stopped. A clinical trial of CJC-1295 in people living with HIV and visceral adiposity was registered on ClinicalTrials.gov, but the compound never progressed to late-phase development and no regulator has ever approved it. The published human dataset consists of early-phase work in healthy volunteers, which is adequate to describe pharmacokinetics and short-term tolerability and inadequate to describe long-term safety or clinical benefit.

For Mod GRF 1-29 the dataset is empty. Literature searches under modified GRF (1-29), Mod GRF 1-29 and tetrasubstituted GRF return no human efficacy or safety trial of the no-DAC peptide. The molecule appears in the analytical and anti-doping literature as a substance to be detected, not as an intervention that has been studied in people.

The correct way to state this is uncomfortable but simple: the better-documented form is the one with the more aggressive pharmacokinetics, and the form usually presented as gentler and more physiological is the one with no human evidence at all. Absence of reported adverse effects in a compound that has never been formally studied is not a safety signal.

What adverse effects have been reported?

In the phase 1 programme, the authors concluded that subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-I and was safe and relatively well tolerated, particularly at the two lower dose levels studied (30 or 60 micrograms per kilogram), and no serious adverse reactions were reported. The events described in that work were predominantly local and transient: injection site reactions such as pain, swelling and induration, sometimes with local urticaria. Headache, gastrointestinal upset and transient vasodilatory symptoms including flushing and warmth were also reported, more frequently at the higher dose levels tested.

Beyond the trial record, there are class-level considerations that apply to any intervention that raises GH and IGF-I for an extended period. Sustained GH excess is associated with insulin resistance and impaired glucose tolerance, fluid retention, joint pain and compression symptoms such as carpal tunnel syndrome. These are known consequences of GH exposure in general rather than findings specific to either form discussed here, but they are the reasons a multi-day half-life is pharmacologically significant rather than merely convenient.

In its compounding review material on CJC-1295, the FDA has cited a risk of immunogenicity for certain routes of administration along with complexities regarding peptide-related impurities and characterisation of the active ingredient. Immunogenicity is a particular concern for albumin conjugates, since the resulting adduct is a modified version of an abundant self-protein.

For Mod GRF 1-29 there is no adverse event dataset to report, because there is no trial. A shorter exposure window plausibly limits the duration of any effect, which is a mechanistic argument and not a safety finding. Impurity-related risks, which depend on manufacturing rather than on pharmacology, apply equally to both forms.

A fuller treatment of the reported and theoretical risks is available in the dedicated article on CJC-1295 side effects. This page is educational only. Neither compound is approved for human use, long-term safety data do not exist for either, and anyone considering anything in this class should speak with a qualified healthcare professional rather than rely on a web page.

How do the two forms compare side by side?

The table below summarises the verifiable differences. Where a cell reads not published, that is a statement about the literature, not an invitation to fill the gap with a number found on a forum.

ParameterMod GRF 1-29CJC-1295 with DAC
Other names in circulationModified GRF (1-29), tetrasubstituted GRF(1-29), CJC-1295 no DACCJC-1295, CJC-1295 DAC, albumin-binding GHRH analogue
Chain length29 residues30 residues
Core substitutionsD-Ala2, Gln8, Ala15, Leu27Identical: D-Ala2, Gln8, Ala15, Leu27
Albumin-binding linkerNoneLys30 bearing a maleimidopropionyl group
Binding to plasma proteinNo covalent bindingCovalent thioether bond to cysteine-34 of serum albumin
Reported molecular weightAbout 3367.9 g/molAbout 3647.18 g/mol
Reported molecular formulaC₁₅₂H₂₅₂N₄₄O₄₂C₁₆₅H₂₆₉N₄₇O₄₆
Measured human half-lifeNot published5.8 to 8.1 days (Teichman et al., 2006)
Reported GH profile in humansNot publishedTrough GH increased 7.5-fold, mean GH 46%, pulse frequency and magnitude unchanged (Ionescu and Frohman, 2006)
IGF-I response in humansNot published1.5 to 3-fold increase for 9 to 11 days after a single administration; above baseline up to 28 days after multiple administrations
Human trials identifiedNoneEarly-phase work in healthy volunteers, plus a proteomic substudy
Animal dataNone specific to the no-DAC formRat pituitary receptor activation; normalised growth in GHRH knockout mice
Accumulation on repeated administrationNot expected given rapid clearanceExpected given the multi-day half-life
Approval statusNot approvedNot approved
Anti-doping statusProhibited at all times under WADA section S2Prohibited at all times under WADA section S2

Read vertically, the table makes the central point of this comparison obvious. The first five rows describe two nearly identical molecules. Every row after that describes two quite different pharmacological situations, all traceable to the single linker.

It also shows why a direct head-to-head verdict is not available. A fair comparison of outcomes would require trials of both forms under the same conditions, and those trials have never been run.

What is the regulatory and anti-doping status of each form?

Neither form holds a marketing authorisation. There is no FDA-approved and no EMA-approved product containing CJC-1295 or modified GRF (1-29) for any indication. Material sold under either name is sold as a research chemical, typically labelled research use only and not for human consumption, and that labelling is a legal classification rather than a quality claim.

In the United States, CJC-1295 was nominated for inclusion on the list of bulk drug substances that may be used in pharmacy compounding under section 503A of the Food, Drug and Cosmetic Act. FDA review material notes that compounded drugs containing CJC-1295 carry a risk of immunogenicity for certain routes of administration and may present complexities regarding peptide-related impurities and characterisation of the active ingredient. The nomination was withdrawn and the substance does not appear on the list of bulk substances approved for 503A compounding, which means compounding is not an available legal pathway for it. Interestingly, some nomination paperwork lumped the modified GRF (1-29) form and the DAC form under a single CJC-1295 heading, which illustrates that the naming confusion described at the top of this page reaches into regulatory documents as well.

In sport, the position is unambiguous and covers both forms. Growth hormone releasing factors, including growth hormone releasing hormone and its analogues, are listed under section S2 of the WADA Prohibited List and are prohibited at all times, in and out of competition. The list names several members of the family explicitly, including CJC-1293, CJC-1295, sermorelin and tesamorelin. Because the no-DAC peptide is itself a GHRH analogue, calling it Mod GRF 1-29 rather than CJC-1295 has no bearing on its prohibited status.

Detection capability has kept pace. Analytical methods for the qualitative identification of GHRH analogues in human plasma using immunoaffinity purification combined with liquid chromatography and high-resolution tandem mass spectrometry were published by Knoop and colleagues in Analytical and Bioanalytical Chemistry in 2016, and screening assays for CJC-1295 and related analogues have also been developed for equine plasma.

National law varies considerably in how it treats possession, importation and supply of unapproved peptides, and nothing in this article constitutes legal advice. Readers should check the rules applicable in their own jurisdiction, and athletes subject to anti-doping regulation should assume that both forms are prohibited.

How can you check what a label or a certificate of analysis actually says?

Because the two forms are sold under overlapping names, the label alone cannot tell you which molecule is in a vial. A rational check starts with the chemical name rather than the marketing name. A vial described only as CJC-1295 is ambiguous. A vial described as tetrasubstituted GRF(1-29) amide, 29 residues, is the no-DAC peptide; a description specifying a thirtieth lysine residue bearing a maleimidopropionyl group, commonly listed under CAS number 446262-90-4, is the DAC form.

The decisive check is mass. The two molecules differ by roughly 279 Da, around 3368 versus 3647. That difference is far larger than the resolution of any routine mass spectrometer, so a mass spectrum on a certificate of analysis settles the question regardless of what the front label says. A certificate showing an observed mass near 3368 describes the no-DAC peptide even if the vial is marketed with DAC in the name. This single number is the most useful verification tool on the page.

Mass spectrometry is also what the scientific literature uses for exactly this purpose. Henninge and colleagues reported in Drug Testing and Analysis in 2010 how an unknown pharmaceutical preparation was analysed by liquid chromatography and high-resolution tandem mass spectrometry, revealing a 29-amino-acid peptide with a C-terminal amide whose sequence was consistent with CJC-1295. Identity questions in this family are resolved by spectra, not by packaging.

Purity claims deserve the same scepticism as identity claims, because the published quality data on commercially obtained peptides are poor. A quality evaluation of synthetic research peptides by Verbeke and colleagues in the Journal of Pharmaceutical Analysis found that only 44.0% of the peptides examined met the required purity, with a large discrepancy between the purity stated on the supplier's certificate of analysis and the in-house analytical result. Worse, an impurity profiling study of the most frequently encountered falsified polypeptide drugs seized on the Belgian market between 2009 and 2017, published by Janvier and colleagues in Talanta, reported purity ranging between 5% and 75% for cysteine-containing peptides and detected the class one elemental impurities arsenic and lead, with arsenic present in its more toxic inorganic form.

A certificate worth reading has specific features: it is batch-specific, with a batch or lot number that matches the vial; it names the testing laboratory and the analysis date; it includes an actual HPLC chromatogram and an actual mass spectrum rather than a table of numbers typed into a template; and it reports the method used. A single undated PDF reused across every product on a site demonstrates nothing. Readers comparing suppliers and documentation practices will find that discussion in the CJC-1295 sourcing overview, and the concentration arithmetic that a certificate implies is handled by the CJC-1295 reconstitution calculator rather than here.

Educational content only. This article describes what has been published about two research compounds; it is not medical advice, it does not recommend use of either compound, and neither is approved for human use. Consult a qualified healthcare professional for any question concerning your health.

Recommended products

Research peptides selected for quality and purity:

Synergy
CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin

Growth Blend

CJC-1295

CJC-1295

Growth Peptide

Ipamorelin

Ipamorelin

Growth Peptide

🏆

Where to buy this peptide?

We analyzed the best suppliers to help you find a quality, lab-tested product.

See our selection →

Test your knowledge

Quick quiz · 6 questions

Frequently Asked Questions

Is Mod GRF 1-29 the same thing as CJC-1295 without DAC?
Yes. Mod GRF 1-29, modified GRF (1-29), tetrasubstituted GRF(1-29) and CJC-1295 no DAC all describe the same 29-residue peptide: the first 29 amino acids of human GHRH carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27). There is no chemical difference between products sold under these labels, only a difference in commercial naming.
Why do specialists call CJC-1295 no DAC a misnomer?
Because the published compound named CJC-1295 is defined by its Drug Affinity Complex. It is a 30-residue molecule whose thirtieth lysine carries a maleimide group that binds albumin. Remove that linker and you no longer have CJC-1295; you have the stabilised GHRH fragment that the literature never called CJC-1295. The qualifier no DAC removes the very feature the name refers to.
Which of the two forms has human clinical data?
Only the DAC form. Teichman and colleagues published pharmacokinetic, pharmacodynamic and tolerability data in healthy adults in 2006, Ionescu and Frohman published overnight growth hormone profiles in healthy men the same year, and a later proteomic substudy examined serum protein changes. Literature searches return no human trial of the tetrasubstituted peptide without DAC, so statements about Mod GRF 1-29 in humans are inferences from a shared mechanism.
How long does each form stay in the body?
For CJC-1295 with DAC, the published serum half-life in healthy adults was 5.8 to 8.1 days, with mean plasma GH elevated 2 to 10-fold for 6 days or more and IGF-I elevated 1.5 to 3-fold for 9 to 11 days after a single administration. For Mod GRF 1-29, no human half-life has been published. The commonly repeated figure of about thirty minutes cannot be traced to a peer-reviewed human study and should be treated as an estimate rather than a measurement.
Does the DAC form flatten natural growth hormone pulses?
Not according to the one study that measured it. Ionescu and Frohman found that one week after a single injection of CJC-1295, trough growth hormone levels had risen 7.5-fold and mean levels 46%, while the frequency and magnitude of secretory pulses were statistically unchanged. Continuous GHRH stimulation raised the interpulse baseline rather than abolishing pulsatility, which is why the paper is titled around the persistence of pulsatile secretion.
Are both forms detectable in anti-doping testing?
Yes. Methods for identifying GHRH analogues in human plasma using immunoaffinity purification followed by liquid chromatography and high-resolution tandem mass spectrometry have been published, and both forms belong to the growth hormone releasing factor family listed under section S2 of the WADA Prohibited List, prohibited at all times. Using the name Mod GRF 1-29 instead of CJC-1295 does not change that status.
Can a certificate of analysis distinguish the two forms?
A proper one can, because the molecules differ by roughly 279 Da: approximately 3368 g/mol for the 29-residue peptide versus approximately 3647 g/mol for the DAC-bearing 30-residue version. An observed mass on a mass spectrum therefore identifies which molecule is present, whatever the vial label claims. A certificate without a chromatogram, without a spectrum and without a batch number that matches the vial provides no useful information. Published quality surveys of commercially obtained research peptides have found substantial discrepancies between stated and measured purity.
Is either form approved for human use?
No. Neither Mod GRF 1-29 nor CJC-1295 is approved as a medicine by the FDA or the EMA for any indication. CJC-1295 was nominated for pharmacy compounding in the United States, but FDA review material cited immunogenicity risk and concerns about peptide-related impurities and active ingredient characterisation, and it does not appear on the approved bulk substances list. Both are sold as research materials, long-term safety data do not exist for either, and this article is educational only. Consult a healthcare professional for any medical question.

Sources

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism. (PubMed)
  2. Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology and Metabolism. (PubMed)
  3. Jetté L, Léger R, Thibaudeau K, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. (academic.oup.com)
  4. Alba M, Fintini D, Sagazio A, et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology. Endocrinology and Metabolism. (PubMed)
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research. (PubMed)
  6. Frohman LA, Downs TR, Heimer EP, Felix AM (1989). Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. The Journal of Clinical Investigation. (PubMed)
  7. Henninge J, Pepaj M, Hullstein I, Hemmersbach P (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. (PubMed)
  8. Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M (2016). Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and Bioanalytical Chemistry. (PMC)
  9. Verbeke F, Wynendaele E, Braet S, D'Hondt M, De Spiegeleer B (2015). Quality evaluation of synthetic quorum sensing peptides used in R&D. Journal of Pharmaceutical Analysis. (PubMed)
  10. Janvier S, Cheyns K, Canfyn M, et al. (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. (PubMed)
  11. Pharmacokinetics study group (1993). Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. PubMed indexed report. (PubMed)
  12. U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA Human Drug Compounding. (fda.gov)
  13. World Anti-Doping Agency (2026). The Prohibited List, section S2: Peptide hormones, growth factors, related substances and mimetics. WADA. (wada-ama.org)
  14. ConjuChem Biotechnologies (registry record) (2005). A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527). ClinicalTrials.gov. (clinicaltrials.gov)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer